Stephens resumed coverage on Cutera with a new price target
$CUTR
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Stephens resumed coverage of Cutera with a rating of Overweight and set a new price target of $78.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/22/2024 | Underperform → Mkt Perform | William Blair | |
| 7/27/2023 | $14.00 → $18.00 | Underweight → Neutral | Piper Sandler |
| 5/11/2023 | Outperform → Mkt Perform | William Blair | |
| 5/10/2023 | $14.00 | Underweight | Piper Sandler |
| 3/30/2023 | Buy → Hold | Maxim Group | |
| 1/31/2023 | Mkt Perform | William Blair | |
| 1/11/2023 | $85.00 → $33.00 | Overweight → Neutral | Cantor Fitzgerald |
| 12/28/2022 | $78.00 → $68.00 | Overweight | Stephens |
William Blair upgraded Cutera from Underperform to Mkt Perform
Piper Sandler upgraded Cutera from Underweight to Neutral and set a new price target of $18.00 from $14.00 previously
William Blair downgraded Cutera from Outperform to Mkt Perform
Cutera, Inc. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, announced today that it will report financial results for the third quarter ended September 30, 2024, after the market closes on Thursday, November 7, 2024. The Company's management will host a conference call to discuss these results and related matters at 1:30 p.m. PT (4:30 p.m ET) that same day. Participants can register for the conference call at the following registration link. Upon registering, a calendar booking will be provided by email including the dial-in details and a unique PIN to access the call. Using this process will by-pass the operator and avoid the call queue. Registration will remai
CUTERA, INC. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, today reported financial results for the second quarter ended June 30, 2024. Consolidated revenue for the second quarter of 2024 of $34.4 million Cash, cash equivalents, and restricted cash of $84.3 million AviClear growth of 41% vs prior year period driven by international capital system sales Service growth of 7% vs prior year period, highlighting improvements in field service and overall customer support Completion of the Q4 2023 corporate restructuring program, and announcement of additional cost reduction initiatives, allowing for both improved cost structure and better organization al
CUTERA, INC. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, and its Japanese subsidiary, Cutera KK, are pleased to announce a strategic partnership with L'Oréal Japan Co. to exclusively promote, market, sell and distribute select SkinCeuticals products to medical and physician-led clinics in Japan. "We are excited about this collaboration with L'Oréal Japan Co. to bring SkinCeuticals' renowned skincare innovations to aesthetic providers in Japan," said Brent Hauser, Cutera's International President. "This agreement underscores our commitment to supporting our existing customer base by expanding access to high-quality skincare solutions that meet the unique needs
4 - CUTERA INC (0001162461) (Issuer)
4 - CUTERA INC (0001162461) (Issuer)
4 - CUTERA INC (0001162461) (Issuer)
SC 13D/A - CUTERA INC (0001162461) (Subject)
SC 13D/A - CUTERA INC (0001162461) (Subject)
SC 13D/A - CUTERA INC (0001162461) (Subject)
8-K - CUTERA INC (0001162461) (Filer)
10-Q - CUTERA INC (0001162461) (Filer)
8-K - CUTERA INC (0001162461) (Filer)
Stephens & Co. analyst George Sellers reiterates Cutera (NASDAQ:CUTR) with a Overweight and maintains $10 price target.
Piper Sandler analyst Matt O'Brien maintains Cutera (NASDAQ:CUTR) with a Neutral and maintains $3 price target.
- SEC Filing
Experienced Healthcare Executive Brings Extensive Financial and Operational Expertise to Cutera Board of Directors CUTERA, INC. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, announced today that Jeryl "Jeri" Hilleman will join its Board of Directors, effective July 12, 2024. Ms. Hilleman brings over 30 years of experience in the healthcare industry, with a proven track record in financial leadership, strategic planning, operational excellence, and corporate governance. Her extensive background in life sciences and medical technology, both as a public company CFO and as a corporate director, will be invaluable to Cutera as it continues to innovate, drive towar
Cutera, Inc. (NASDAQ:CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, is pleased to announce the appointment of Stephana Patton, Ph.D., J.D. as Chief Legal Officer, effective November 13, 2023. Dr. Patton will report directly to Taylor Harris, Cutera's Chief Executive Officer, and will be responsible for leading the legal, compliance, intellectual property and human resources functions. Dr. Patton brings over two decades of legal experience, focused on the life sciences industry both in private practice and as in-house counsel, to Cutera. Taylor Harris, Chief Executive Officer, said, "I am thrilled to welcome Stephana to the Cutera team. Step
Hauser Brings Over 20 Years of Aesthetics Industry Experience in Markets Across the Globe Cutera, Inc. (NASDAQ:CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, is pleased to announce the appointment of Brent Hauser as President, International, effective October 2, 2023. Mr. Hauser will report directly to Taylor Harris, Cutera's Chief Executive Officer, and will be responsible for commercial performance in existing international markets, expansion into new geographies, and the international launch of AviClear, the company's pioneering energy-based device for the treatment of mild to severe acne, in 2024. Mr. Hauser brings over 20 years of aest
Cutera, Inc. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, announced today that it will report financial results for the third quarter ended September 30, 2024, after the market closes on Thursday, November 7, 2024. The Company's management will host a conference call to discuss these results and related matters at 1:30 p.m. PT (4:30 p.m ET) that same day. Participants can register for the conference call at the following registration link. Upon registering, a calendar booking will be provided by email including the dial-in details and a unique PIN to access the call. Using this process will by-pass the operator and avoid the call queue. Registration will remai
CUTERA, INC. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, today reported financial results for the second quarter ended June 30, 2024. Consolidated revenue for the second quarter of 2024 of $34.4 million Cash, cash equivalents, and restricted cash of $84.3 million AviClear growth of 41% vs prior year period driven by international capital system sales Service growth of 7% vs prior year period, highlighting improvements in field service and overall customer support Completion of the Q4 2023 corporate restructuring program, and announcement of additional cost reduction initiatives, allowing for both improved cost structure and better organization al
CUTERA, INC. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, announced today that it will report financial results for the second quarter ended June 30, 2024, after the market closes on Thursday, August 8, 2024. The Company's management will host a conference call to discuss these results and related matters at 1:30 p.m. PT (4:30 p.m ET) that same day. Participants can register for the conference call by following registration link. Upon registering, a calendar booking will be provided by email including the dial-in details and a unique PIN to access the call. Using this process will by-pass the operator and avoid the call queue. Registration will remain open u